Related Experiment Video
Updated: May 16, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia
Yan Chen Shang1, Zhao Zhong Chong, Shaohui Wang
1Laboratory of Cellular and Molecular Signaling, New Jersey Health Sciences University, Newark, NJ 07101, USA.
Abstract:
More than 110 million individuals will suffer from cognitive loss worldwide by the year 2050 with a majority of individuals presenting with Alzheimer's disease (AD). Yet, successful treatments for etiologies that involve β.-amyloid (Aβ.) toxicity in AD remain elusive and await novel avenues for drug development. Here we show that Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) controls the post-translational phosphorylation of Akt1, p70S6K, and AMP activated protein kinase (AMPK) to the extent that tuberous sclerosis complex 2 (TSC2) (Ser1387) phosphorylation, a target of AMPK, is decreased and TSC2 (Thr1462) phosphorylation, a target of Akt1, is increased. The ability of WISP1 to limit TSC2 activity allows WISP1 to increase the activity of p70S6K, since gene silencing of TSC2 further enhances WISP1 phosphorylation of p70S6K. However, a minimal level of TSC2 activity is necessary to modulate WISP1 cytoprotection that may require modulation of mTOR activity, since gene knockdown of TSC2 impairs the ability of WISP1 to protect microglia against apoptotic membrane phosphatidylserine (PS) exposure, nuclear DNA degradation, mitochondrial membrane depolarization, and cytochrome c release during Aβ. exposure.
Insights
Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) influences key proteins in Alzheimer's disease (AD) pathology. WISP1 regulates cell survival pathways, offering potential new therapeutic targets for AD and cognitive loss.
Area of Science:
- Neuroscience
- Molecular Biology
- Cell Biology
Background:
- Alzheimer's disease (AD) affects millions globally, with β-amyloid (Aβ) toxicity being a key pathological feature.
- Current treatments for AD targeting Aβ toxicity are limited, necessitating novel drug development strategies.
Purpose of the Study:
- To investigate the role of Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) in the molecular pathways implicated in AD.
- To elucidate how WISP1 influences cellular responses to Aβ exposure.
Main Methods:
- Western blotting to assess protein phosphorylation.
- Gene silencing techniques (siRNA) to manipulate WISP1 and TSC2 expression.
- Apoptosis assays (phosphatidylserine exposure, DNA degradation, mitochondrial depolarization, cytochrome c release) in microglia exposed to Aβ.
Main Results:
- WISP1 modulates the phosphorylation of Akt1, p70S6K, and AMP-activated protein kinase (AMPK).
- WISP1 influences the phosphorylation of tuberous sclerosis complex 2 (TSC2) at Ser1387 (AMPK target) and Thr1462 (Akt1 target).
- WISP1-mediated reduction in TSC2 activity enhances p70S6K activity, but TSC2 activity is crucial for WISP1-induced cytoprotection against Aβ toxicity in microglia.
Conclusions:
- WISP1 plays a significant role in regulating cellular signaling pathways relevant to AD pathogenesis.
- WISP1's cytoprotective effects against Aβ toxicity are dependent on a basal level of TSC2 activity, potentially involving mTOR signaling.
- WISP1 represents a potential therapeutic target for mitigating Aβ-induced neurotoxicity in Alzheimer's disease.
More Related Videos
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
06:25Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
Related Concept Videos
Microtubule Associated Proteins (MAPs)
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...